SCHEMBL1011071

SCHEMBL1011071

COC(=O)C(CC1CCCC1)n1nc(Oc2ccccc2)ccc1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 1/20 0.42
METAP2 P50579 1/20 0.39
METAP1 P53582 1/20 0.39
CTSS P25774 2/20 0.37
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
NAAA Q02083 1/20 0.35
KMT2A Q03164 2/20 0.35
P2RX3 P56373 1/20 0.35
CTSL P07711 1/20 0.35
MEN1 O00255 1/20 0.35
GCK P35557 1/20 0.35
ATM Q13315 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CCKBR P32239 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008857 0.89 NPY5R (0.40) NPY5RMETAP2METAP1KDM4ENPC1
SCHEMBL4301715 0.82 GCK (0.53) NPY5RMETAP2METAP1GCK
SCHEMBL1009289 0.80 NPY5R (0.44) NPY5RMETAP2METAP1CTSSSMN1; SMN2
SCHEMBL1008656 0.77 GCK (0.38) GCK
SCHEMBL1064978 0.73 NPY5R (0.44) NPY5RMETAP2METAP1CTSSNAAA
SCHEMBL2701446 0.73 NPY5R (0.44) NPY5RMETAP2METAP1CTSSNAAA
SCHEMBL1008317 0.71 NPY5R (0.36) NPY5RCTSSCTSLGCKATM
SCHEMBL1008591 0.70 GCK (0.37) NPC1RAB9AGCK
SCHEMBL1065040 0.70 L3MBTL1 (0.40) METAP2METAP1KDM4EKMT2AGCK
SCHEMBL1007886 0.70 POLB (0.34) NPY5RMETAP2METAP1GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK NPY5R 2254/4885METAP2 1286/4885METAP1 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.